A Study of SDI-118 in Participants in Remission From Depression

Depression in Remission Clinical Trial

Official title:
A Phase Ib, Exploratory, Double Blind, Placebo Controlled, Parallel Group, Study of SDI-118 to Evaluate Safety, Tolerability, and Pharmacodynamics Including Cognitive Function in Male and Female Participants in Remission From Depression

Status Withdrawn

Clinical Trial Summary

This is a multi-center, double-blind, randomized, placebo-controlled study to determine the safety, tolerability, and pharmacodynamics of SDI-118 in a once daily (QD) dosing regimen on male and female study participants reporting with cogntive decline and who in remission from depression.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05212116
Study type	Interventional
Source	Syndesi Therapeutics
Contact
Status	Withdrawn
Phase	Phase 1
Start date	September 16, 2021
Completion date	March 11, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04211467` - A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Depression
Recruiting	`NCT06145984` - Mechanisms of Change of Positive Interventions in Reducing Vulnerability for Depression	N/A
Completed	`NCT05220228` - Prucalopride and Cognition in Recovered Depression	N/A
Completed	`NCT05111665` - Decentering and Relapse/Recurrence in MBCT for Depression in Adults	N/A
Recruiting	`NCT02821975` - Cognitive Computer Training in Patients With Depression	N/A
Recruiting	`NCT05585775` - Mood and Thought Process Study	N/A